BR112022011555A2 - Composição farmacêutica de um composto pirazólico disperso em uma matriz polimérica - Google Patents

Composição farmacêutica de um composto pirazólico disperso em uma matriz polimérica

Info

Publication number
BR112022011555A2
BR112022011555A2 BR112022011555A BR112022011555A BR112022011555A2 BR 112022011555 A2 BR112022011555 A2 BR 112022011555A2 BR 112022011555 A BR112022011555 A BR 112022011555A BR 112022011555 A BR112022011555 A BR 112022011555A BR 112022011555 A2 BR112022011555 A2 BR 112022011555A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
polymeric matrix
compound dispersed
pyrazolic
pyrazolic compound
Prior art date
Application number
BR112022011555A
Other languages
English (en)
Inventor
D Kulczar Christopher
Ryan Schenck Luke
Li Yongjun
C F Rumondor Alfred
Original Assignee
Intervet Int Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet Int Bv filed Critical Intervet Int Bv
Publication of BR112022011555A2 publication Critical patent/BR112022011555A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

COMPOSIÇÃO FARMACÊUTICA DE UM COMPOSTO PIRAZÓLICO DISPERSO EM UMA MATRIZ POLIMÉRICA. Uma composição farmacêutica de composto pirazólico disperso em uma matriz polimérica e um método de uso do mesmo para tratar dermatite atópica.
BR112022011555A 2019-12-20 2020-12-18 Composição farmacêutica de um composto pirazólico disperso em uma matriz polimérica BR112022011555A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962951162P 2019-12-20 2019-12-20
PCT/EP2020/086918 WO2021123088A1 (en) 2019-12-20 2020-12-18 A pharmaceutical composition of a pyrazole compound dispersed in a polymer matrix

Publications (1)

Publication Number Publication Date
BR112022011555A2 true BR112022011555A2 (pt) 2022-08-30

Family

ID=74184582

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022011555A BR112022011555A2 (pt) 2019-12-20 2020-12-18 Composição farmacêutica de um composto pirazólico disperso em uma matriz polimérica

Country Status (11)

Country Link
US (1) US20230062746A1 (pt)
EP (1) EP4076407B1 (pt)
JP (1) JP2023506920A (pt)
KR (1) KR20220119023A (pt)
CN (1) CN114929203A (pt)
AU (1) AU2020408173A1 (pt)
BR (1) BR112022011555A2 (pt)
CA (1) CA3163951A1 (pt)
ES (1) ES2963626T3 (pt)
MX (1) MX2022007580A (pt)
WO (1) WO2021123088A1 (pt)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2679028A1 (en) * 2007-02-23 2008-08-28 Avera Pharmaceuticals, Inc. Pharmaceutical formulation
CN102231990B (zh) * 2008-08-13 2013-09-25 沃泰克斯药物股份有限公司 N-[2，4-双(1，1-二甲基乙基)-5-羟基苯基]-1，4-二氢-4-氧代喹啉-3-甲酰胺的药物组合物和其给药
WO2013040863A1 (en) 2011-09-22 2013-03-28 Merck Sharp & Dohme Corp. Cycloalkylnitrile pyrazole carboxamides as janus kinase inhibitors
PE20151335A1 (es) * 2013-01-22 2015-09-18 Hoffmann La Roche Composicion farmaceutica con biodisponibilidad mejorada
DK3555074T3 (da) 2016-12-14 2022-10-03 Intervet Int Bv Aminopyrazoler som selektive januskinasehæmmere
WO2019091438A1 (zh) * 2017-11-10 2019-05-16 苏州信诺维医药科技有限公司 作为btk抑制剂的5-氨基吡唑甲酰胺化合物的无定型固体分散体

Also Published As

Publication number Publication date
CN114929203A (zh) 2022-08-19
ES2963626T3 (es) 2024-04-01
JP2023506920A (ja) 2023-02-20
AU2020408173A1 (en) 2022-06-09
EP4076407A1 (en) 2022-10-26
US20230062746A1 (en) 2023-03-02
EP4076407B1 (en) 2023-08-23
WO2021123088A1 (en) 2021-06-24
MX2022007580A (es) 2022-07-19
KR20220119023A (ko) 2022-08-26
CA3163951A1 (en) 2021-06-24

Similar Documents

Publication Publication Date Title
CL2018001172A1 (es) Polipéptidos del dominio extracelular de cd80 y su uso en el tratamiento del cáncer
BR112017025574A2 (pt) composições e métodos para degradação de proteínas de má dobra
BR112017023576A2 (pt) Método para tratar uma disfunção proliferativa de células b
BR112018009437A2 (pt) controle de níveis de oxirredução celular
CL2017000288A1 (es) Encapsulación de compuestos hidrofóbicos biologicamente activos
BR112018070133A2 (pt) dispersão, uso desta e método para a inativação fotodinâmica de micro-organismos
BR112017002751A2 (pt) composições de combustível fluido, processo para preparação de uma composição fluida, e uso de composição fluida
CL2014002348A1 (es) Compuestos derivados de fenicol; composicion farmaceutica que los comprende; y su uso para controlar o tratar infecciones bacterianas en ganado.
BR112018001128A2 (pt) composições para proteção uv
BR112018074283A2 (pt) composição e métodos para terapia com microbiota.
BR112016002613A2 (pt) método de cimentação, composição de cimento de pega lenta e sistema para a cimentação
BR112021026476A2 (pt) Aditivos para agentes corantes e método de uso dos mesmos
MX2017012895A (es) Composicion veterinaria de extracto de algas marinas y andrographis sp, util para tratar infeccion en peces.
BR112017023969A2 (pt) ?microrganismo do gênero escherichia que produz l-triptofano e um método para produzir l- triptofano com o uso do mesmo?
BR112018002097A2 (pt) métodos de distribuição de micróbios ou enzimas produtoras de carbonato de cálcio furo abaixo
CO2019010605A2 (es) Material mixto de caucho y procedimiento para obtener el mismo campo tecnológico
BR112016012058A2 (pt) Composição de corante disperso, corante disperso e método de preparação e uso dos mesmos
BR112022011555A2 (pt) Composição farmacêutica de um composto pirazólico disperso em uma matriz polimérica
BR112018069115A2 (pt) composições, composições de revestimento aquosas e métodos para melhorar a estabilidade de congelamento/descongelamento de composições de revestimento aquosas
AR116648A1 (es) Microorganismos oxidantes de amoníaco para uso en el control de plagas
BR112022011786A2 (pt) Composição farmacêutica de pirazol
BR112018007815A2 (pt) composição agroquímica granular
MX2020003991A (es) Método para diseñar un hormigón autocurable adicionado con un hormigón permeable que contiene materiales biológicos.
BR112022001329A2 (pt) Anticorpo biespecífico anti-egfr/anti-4-1bb e uso do mesmo
BR112014028527A2 (pt) formulação de cura anaeróbica, uso da formulação e método para micro-encapsulamento de um acelerador de polimerização

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]